1、June 2025ASCO 2025 Impact SurveyConducted by Syneos HealthSurvey Objectives and Sample Overview3SYNEOS HEALTHCONFIDENTIAL.AUTHORIZED USE ONLY.Syneos Health Conducted a Research Survey to Understand the Impact of the ASCO 2025 ConferenceUnderstand oncologists perceptions of the ASCO 2025 conference I

2、dentify and explore data oncologists consider most impactful from this conferenceUnderstand how new data may impact future treatment of cancer 4SYNEOS HEALTHCONFIDENTIAL.AUTHORIZED USE ONLY.Survey Sample Inclded 81 Practicing Oncologists who Attended the 2025 ASCO Annual Meeting In-PersonSample Size

3、#Board-certified Oncologists81Clinical ExperienceMean Years in Clinical Practice13330Time in Direct Patient CareMean%Time86%Practice Setting%Oncologists by Current Practice SettingCancers Treated%of Respondents Treating the Following CancersPatient Management ExperienceAverage#Cancer Patients(Any Ty

4、pe)Treated per Year49%12%23%15%682Academic Medical Center or Teaching HospitalGroup,Solo or Clinical Private PracticeCommunity HospitalNCCN or NCI Cancer Center81%74%69%63%63%52%51%46%37%Digestive/GastrointestinalLung/RespiratoryHematologicGenitourinaryBreastGynecologicHead and NeckSkinNeurologicExe

5、cutive Summary andSurvey Insights6SYNEOS HEALTHCONFIDENTIAL.AUTHORIZED USE ONLY.This analysis is based on answers provided by a sample of 81 oncologists treating a range of cancer types and who attended ASCO 2025The excitement for data being presented at ASCO 2025 was higher as compared to last year

6、Expectations&Perceptions Treatment ModalityRespondents were most excited about multi-targeted antibodies(e.g.,bispecifics)and ADCs among targeted modalities,whereas autologous CAR-T and TCR therapies were rated highest among cell-based treatment modalitiesMOA ExcitementBRAF V600E and HER2 are the hi